Thyrotoxicosis: gross acropachy and pretibial myxoedema J S Shaheen (medical student) F G Ellis MS FRCS A Marvasti MD Guy's Hospital, London SEI Pretibial myxoedema and thyroid acropachy associated with thyrotoxicosis are seen rarely. A case with gross signs of these conditions is now reported.
). Gross circumferential swelling of the shins and ankles with oedema and nodule formation ( Figure 2 ) was present. He had no diplopia, ophthalmoplegia, tremor or myopathy.
His thyroid function tests confirmed gross hyperthyroidism (T3 = 8). A thyroid scan demonstrated diffuse enlargement and high uptake consistent with thyrotoxicosis. A skin biopsy of the left big toe showed excess acid mucopolysaccharide in the upper dermis with enlarged fibroblasts and separated collagen bundles, consistent with pretibial myxoedema. On X-ray there was periosteal new bone formation at first, fourth and fifth metacarpals, all proximal phalanges and on the tibiae. A bone scan revealed increased periosteal bone activity typical of thyroid acropachy.
The patient was treated by subtotal thyroidectomy (74 g), continuous occlusive beclomethasone cream 0.025% applied to the legs, ablation of the residual thyroid with 131, maintenance thyroxine, and bilateral lateral tarsorrhaphy.
Discussion
The frequency of pretibial myxoedema in adults with thyrotoxicosis is 4%. It can occur with or without Graves' disease, and age, sex, duration or degree of thyrotoxicosis are unrelated to its development. It does not parallel the ocular changes if present. It presents before or after treatment and is usually asymptomatic. The lesion is raised, pink and firm, and prominent hair follicles give a peau d'orange appearance. The patches vary in size and may extend from the skin on to the dorsum of the feet. There may be increased sweating or hypertrichosis over the lesion. There are three types: (1) sharply circumscribed with nodule formation; (2) diffuse, producing solid, non-pitting oedema; (3) elephantiasis form with oedema and nodule formation.
The micropathology shows an atrophic epidermis with a flattened epidermal-dermal junction. The dermis is thickened due to an increase of mucopolysaccharide sixteen times normal, the bulk being hyaluronic acid. The latter causes the collagen to appear fragmented.
The aetiology is still unclear, but antibodies from the class of thyroid-stimulating immunoglobulins (TSI) are involved. High serum levels of TSI are found which return to normal after successful treatment. Direct stimulation of receptors on the fibroblasts is thought to cause the production of mucopolysaccharide. Serum levels of antibody equal those in the dermis, which discounts local antibody formation. Treatment involves continuous application of concentrated steroid cream under an occlusive dressing for many months. Spontaneous remission occurs in 50% but regression may be very slow.
Thyroid acropachy is a rare condition associated with pretibial myxoedema and exophthalmos. Its incidence is less than 1% and it occurs any time from weeks to over 25 years following the onset of hyperthyroidism, but more than 95% of patients develop it following treatment of thyrotoxicosis. The signs are finger and toe clubbing, and subcutaneous tissue swelling of the extremities, which are pale and firm with normal skin temperature; stiffness is the only symptom. The aetiology is thought to be similar to that in pretibial myxoedema, that is antibodies (TSI) act on the subcutaneous tissues and bones of the extremities; The -differential diagnosis is from hypertrophic pulmonary osteoarthropathy. On X-ray, spicules of new periosteal bone are seen affecting the metacarpals, classically the ulnar side of the fifth metacarpal and the radial side of the others. The proximal phalanges and the radial ends of the radius, ulna and distal phalanges may be affected. Bone scan shows areas of increased bone activity associated with radiological changes. There is no treatment available.
Thyroid-stimulating immunoglobulin (TSI) is an
IgG1. It mimics thyroid-stimulating hormone (TSH) by stimulating cyclic adenosine monophosphate production, radioactive iodine uptake and colloid droplet formation. TSI and TSH appear to compete for the same binding site on the TSH receptor. In patients with Graves' disease there are abnormalities in cell-mediated and humoral immunity. As these are controlled by T lymphocytes, it is possible that T cell control is malfunctioning. Normal control is made by suppressor T lymphocytes which suppress abnormal clones of T helper cells directed against self. In Graves' disease a randomly mutating clone of helper T cells directed against thyroid survives2, and these direct B cells to produce polyclonal thyroid autoantibodies (TSI). There is an HLA-DR3 association with Graves' diseaseand the class II major histocompatibility antigens encoded by genes in the HLA-D region are important in the presentationof antigens and regulation of immune response3. So it seems that a genetic predisposition is involved in the deficit in immune control. Endo et al.4 showed that TSI will bind to thyroid plus tissues outside the gland, e.g. fat cells. In this way various manifestations of an autoimmune reaction occur together, i.e. ophthalmopathy, pretibial myxoedema, thyroid acropachy. The explanation is that immune control affecting several clones of helper T-cells are made which cause antibodies (TSI) to be produced which each affect different tissues, i.e. eye, dermis, bones. Some recent work by Rennie et al.' has demonstrated in-vitro suppression of autoantibodies to thyroglobulin in Hashimoto's disease. Perhaps a similar technique could be developed to suppress the autoimmune mechanism in Graves' disease and so offer useful treatment of the signs described as an adjunct to surgery. 
